Appropriateness criteria for coronary revascularization in stable-angina patients.
作者信息
Silva Guilherme V
机构信息
Stem Cell Center, Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, Texas 77030, USA.
出版信息
Tex Heart Inst J. 2012;39(2):235-6.
Abstract
摘要
相似文献
1
Appropriateness criteria for coronary revascularization in stable-angina patients.
Tex Heart Inst J. 2012;39(2):235-6.
2
Left anterior descending coronary artery revascularization patient-tailored therapy?
JACC Cardiovasc Interv. 2008 Oct;1(5):492-3. doi: 10.1016/j.jcin.2008.08.012.
3
The Gordian knot of revascularization for multivessel coronary artery disease.
J Thorac Cardiovasc Surg. 2011 Jul;142(1):241-2; author reply 242-3. doi: 10.1016/j.jtcvs.2011.02.042.
4
Clinical outcome following conservative vs revascularization therapy in patients with stable coronary artery disease and borderline fractional flow reserve measurements.
Clin Cardiol. 2010 Feb;33(2):77-83. doi: 10.1002/clc.20693.
5
Coronary artery disease: Risk models for revascularization--the search continues.
Nat Rev Cardiol. 2012 Apr 17;9(6):316-8. doi: 10.1038/nrcardio.2012.57.
6
Coronary artery disease: revascularization strategies for patients with CAD and diabetes.
Nat Rev Cardiol. 2010 Jul;7(7):364-6. doi: 10.1038/nrcardio.2010.82.
7
Percutaneous coronary revascularization in patients with formerly "refractory angina pectoris in end-stage coronary artery disease" - not "end-stage" after all.
BMC Cardiovasc Disord. 2009 Aug 28;9:42. doi: 10.1186/1471-2261-9-42.
8
Ten-year outcomes of patients randomized to surgery, angioplasty, or medical treatment for stable multivessel coronary disease: effect of age in the Medicine, Angioplasty, or Surgery Study II trial.
J Thorac Cardiovasc Surg. 2013 Nov;146(5):1105-12. doi: 10.1016/j.jtcvs.2012.08.015. Epub 2012 Aug 31.
9
Comparing procedural risks to select the optimal revascularization strategy: certainty in an uncertain anatomical world.
Catheter Cardiovasc Interv. 2011 Feb 1;77(2):313-4. doi: 10.1002/ccd.22783.
10
Class I indications for coronary artery bypass graft surgery: what is the appropriate therapy for patients with multivessel coronary disease?
JACC Cardiovasc Interv. 2009 Jul;2(7):622-3. doi: 10.1016/j.jcin.2009.05.009.
本文引用的文献
1
Impact of ischaemia and scar on the therapeutic benefit derived from myocardial revascularization vs. medical therapy among patients undergoing stress-rest myocardial perfusion scintigraphy.
Eur Heart J. 2011 Apr;32(8):1012-24. doi: 10.1093/eurheartj/ehq500. Epub 2011 Jan 21.
2
Management of stable coronary artery disease.
Lancet. 2010 Feb 27;375(9716):763-72. doi: 10.1016/S0140-6736(10)60168-7.
3
ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for Coronary Revascularization: A Report of the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, and the American Society of Nuclear Cardiology: Endorsed by the American Society of Echocardiography, the Heart Failure Society of America, and the Society of Cardiovascular Computed Tomography.
Circulation. 2009 Mar 10;119(9):1330-52. doi: 10.1161/CIRCULATIONAHA.108.191768. Epub 2009 Jan 8.
4
Optimal medical therapy with or without PCI for stable coronary disease.
N Engl J Med. 2007 Apr 12;356(15):1503-16. doi: 10.1056/NEJMoa070829. Epub 2007 Mar 26.
5
Long-term outcome in elderly patients with chronic angina managed invasively versus by optimized medical therapy: four-year follow-up of the randomized Trial of Invasive versus Medical therapy in Elderly patients (TIME).
Circulation. 2004 Sep 7;110(10):1213-8. doi: 10.1161/01.CIR.0000140983.69571.BA. Epub 2004 Aug 30.
6
Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary-artery disease (TIME): a randomised trial.
Lancet. 2001 Sep 22;358(9286):951-7. doi: 10.1016/S0140-6736(01)06100-1.
Zotero 插件